TESARO Inc (TSRO) - Financial and Strategic SWOT Analysis Review

June 2018 | 60 pages | ID: T4672834339EN
GlobalData

Abstracts

TESARO Inc (TSRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The company’s product portfolio includes ZEJULA (niraparib), to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and VARUBI (rolapitant) for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO sells its products directly to hospitals and clinics, and to a limited number of specialty distributors and pharmacy providers in the US and to certain wholesale distributors in Europe. TESARO is headquartered in Waltham, Massachusetts, the US.

TESARO Inc Key Recent Developments

May 08,2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients
May 03,2018: TESARO Announces First-Quarter 2018 Operating Results
Apr 19,2018: TESARO to Receive 2018 Partnership Award at CancerCare Gala
Feb 27,2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Nov 07,2017: TESARO Announces Third-Quarter 2017 Operating Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

TESARO Inc - Key Facts
TESARO Inc - Key Employees
TESARO Inc - Key Employee Biographies
TESARO Inc - Major Products and Services
TESARO Inc - History
TESARO Inc - Company Statement
TESARO Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
TESARO Inc - Business Description
TESARO Inc - Corporate Strategy
TESARO Inc - SWOT Analysis
SWOT Analysis - Overview
TESARO Inc - Strengths
TESARO Inc - Weaknesses
TESARO Inc - Opportunities
TESARO Inc - Threats
TESARO Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
TESARO Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 08, 2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients
May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results
Apr 19, 2018: TESARO to Receive 2018 Partnership Award at CancerCare Gala
Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results
Sep 28, 2017: TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller
Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results
Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results
Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

TESARO Inc, Key Facts
TESARO Inc, Key Employees
TESARO Inc, Key Employee Biographies
TESARO Inc, Major Products and Services
TESARO Inc, History
TESARO Inc, Subsidiaries
TESARO Inc, Key Competitors
TESARO Inc, Ratios based on current share price
TESARO Inc, Annual Ratios
TESARO Inc, Annual Ratios (Cont.1)
TESARO Inc, Interim Ratios
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
TESARO Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

TESARO Inc, Performance Chart (2013 - 2017)
TESARO Inc, Ratio Charts
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Sandoz Inc
Pfizer Inc
Novartis AG
Merck & Co Inc
Loxo Oncology Inc
EMD Serono Inc
Eisai Inc
Clovis Oncology Inc
Bristol-Myers Squibb Co
AstraZeneca Plc
AbbVie Inc